Mancia G, Schumacher H, Redon J, Verdecchia P, Scmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pres- sure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727 1736. 164. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf F; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial. J Am Coll Cardiol. 2012;59:74 83. 165. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C. Achievement and safety of a low blood pressure goal in chronic re- nal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641 650. 166. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-lordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scvanziani R, Sorba G, Zoccali C, Remuzzi G; REIN-2 Study Group. Blood-pressure control for renoprotection in pa- tients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939 946. 167. Mancia G, Fagard R, Narkiewicz K, Red n J, Zanchetti A, B hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee D E, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis A J, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 